Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo

Cancer Research

Volumn 66, Issue 16, 2006, Pages 7983-7990

  Kim, Kwan Sik ^a,b   Sengupta, Saubhik ^a   Berk, Michael ^a   Kwak, Yong Geun ^c   Escobar, Pedro F ^a   Belinson, Jerome ^a   Mok, Samuel C ^d   Xu, Yan ^a,e  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Research Institute of Clinical Medicine   (South Korea)

^c Chonbuk National University Medical School   (South Korea)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DIMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; COLLAGEN TYPE 1; GELDANAMYCIN; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYSOPHOSPHATIDIC ACID; PHOSPHOLIPASE A2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IN VIVO STUDY; MOUSE; NONHUMAN; OVARY CANCER; OVARY METASTASIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING;

CELL HYPOXIA; CELL MOVEMENT; FEMALE; HUMANS; LYSOPHOSPHOLIPIDS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33748056087     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4381     Document Type: Article

References (47)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Kohn EC, Mills GB, Liotta L. Promising directions for the diagnosis and management of gynecological cancers. Int J Gynaecol Obstet 2003;83 Suppl 1:203-9.
3. Mills GB, Fang X, Lu Y, et al. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol 2003;88:S88-92;discussion S93-86.
4. Karlan BY, Krakow D. Genetic aspects of ovarian cancer. Curr Opin Obstet Gynecol 1994;6:105-10.
5. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC, Jr. Pathogenesis of ovarian cancers. J Soc Gynecol Investig 1994;1:181-90.
6. Pickel H, Lahousen M, Stettner H, Girardi F. The spread of ovarian cancer. Baillieres Clin Obstet Gynaecol 1989;3:3-12.
7. Gardner MJ, Jones LM, Catterall JB, Turner GA. Expression of cell adhesion molecules on ovarian tumour cell lines and mesothelial cells, in relation to ovarian cancer metastasis. Cancer Lett 1995;91:229-34.
8. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995;309:933-40.
9. Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995;1:1223-32.
10. Xu Y, Xiao YJ, Zhu K, et al. Unfolding the pathophysiological role of bioactive lysophospholipids. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:23-32.
11. Sengupta S, Wang Z, Tipps R, Xu Y. Biology of LPA in health and disease. Semin Cell Dev Biol 2004;15:503-12.
12. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003;3:582-91.
13. Huang MC, Lee HY, Yeh CC, Kong Y, Zaloudek CJ, Goetzl EJ. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2). Oncogene 2004;23:122-9.
14. Sengupta S, Xiao YJ, Xu Y. A novel laminin-induced LPA autocrme loop in the migration of ovarian cancer cells. FASEB J 2003;17:1570-2.
15. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
16. Quintero M, Mackenzie N, Brennan PA. Hypoxia-inducible factor 1 (HIF-1) in cancer. Eur J Surg Oncol 2004;30:465-8.
17. Brown MR, Blanchette JO, Kohn EC. Angiogenesis in ovarian cancer. Baillieres Best Pract Res Clin Obstet Gynaecol 2000;14:901-18.
18. Chambers SK, Gertz RE, Jr., Ivins CM, Kacinski BM. The significance of urokinase-type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer. Cancer 1995;75:1627-33.
19. Schwartz BM, Hong G, Morrison BH, et al. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells. Gynecol Oncol 2001;81:291-300.
20. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001;93:762-8.
21. Pustilnik TB, Estrella V, Wiener JR, et al. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res 1999;5:3704-10.
22. Fang X, Yu S, Bast RC, et al. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem 2004;279:9653-61.
23. Repesh LA. A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 1989;9:192-208.
24. Lu J, Xiao YJ, Baudhuin LM, Hong G, Xu Y. Role of ether-linked lysophosphatidic acids in ovarian cancer cells. J Lipid Res 2002;43:463-76.
25. Ren J, Xiao XJ, Singh LS, et al. Lysophosphatidic acid is constitutively produced by human peritoneal mesothelial cells and enhances adhesion, migration and invasion of ovarian cancer cells. Cancer Res 2006;66:3006-14.
26. Mabjeesh NJ, Post DE, Willard MT, et al. Geldanamycin induces degradation of hypoxia-inducible factor 1α protein via the proteosome pathway in prostate cancer cells. Cancer Res 2002;62:2478-82.
27. Nguyen DM, Desai S, Chen A, Weiser TS, Schrump DS. Modulation of metastasis phenotypes of non-small cell lung cancer cells by 17-allylamino 17-demethoxy geldanamycin. Ann Thorac Surg 2000;70:1853-60.
28. Vasilevskaya IA, O'Dwyer PJ. Effects of geldanamycin on signaling through activator-protein 1 in hypoxic HT29 human colon adenocarcinoma cells. Cancer Res 1999;59:3935-40.
29. Piccinno R, Puopolo M, Rigault De La Longrais IA, Fracchioli S, Massobrio M, Katsaros D. Growth factors in epithelial ovarian cancer. Minerva Ginecol 2002;54:33-52.
30. Xiao YJ, Schwartz B, Washington M, et al. Electrospray ionization mass spectrometry analysis of lysophospholipids in human ascitic fluids: comparison of the lysophospholipid contents in malignant vs nonmalignant ascitic fluids. Anal Biochem 2001;290:302-13.
31. Xiao Y, Chen Y, Kennedy AW, Belinson J, Xu Y. Evaluation of plasma lysophospholipids for diagnostic significance using electrospray ionization mass spectrometry (ESI-MS) analyses. Ann N Y Acad Sci 2000;905:242-59.
32. Kiguchi K, Kubota T, Aoki D, et al. A patient-like orthotopic implantation nude mouse model of highly metastatic human ovarian cancer. Clin Exp Metastasis 1998;16:751-6.
33. Eder AM, Sasagawa T, Mao M, Aoki J, Mills GB. Constitutive and lysophosphatidic acid (LPA)-induced LPA production: role of phospholipase D and phospholipase A2. Clin Cancer Res 2000;6:2482-91.
34. Xu Y, Xiao YJ, Baudhuin LM, Schwartz BM. The role and clinical applications of bioactive lysolipids in ovarian cancer. J Soc Gynecol Investig 2001;8:1-13.
35. Massazza G, Tomasini A, Lucchini V, et al. Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy. Int J Cancer 1989;44:494-500.
36. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In viro and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-6.
37. Hollingshead M, Alley M, Burger AM, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol 2005;56:115-25.
38. Knisely JP, Rockwell S. Importance of hypoxia in the biology and treatment of brain tumors. Neuroimaging Clin N Am 2002;12:525-36.
39. Baker DL, Morrison P, Miller B, et al. Plasma lysophosphatidic acid concentration and ovarian cancer. JAMA 2002;287:3081-2.
40. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3:721-32.
41. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425:407-10.
42. Murakami M. Hot topics in phospholipase A2 field. Biol Pharm Bull 2004;27:1179-82.
43. Sa G, Murugesan G, Jaye M, Ivashchenko Y, Fox PL. Activation of cytosolic phospholipase A2 by basic fibroblast growth factor via a p42 mitogen-activated protein kinase-dependent phosphorylation pathway in endothelial cells. J Biol Chem 1995;270:2360-6.
44. Bernatchez PN, Tremblay F, Rollin S, Neagoe PE, Sirois MG. Sphingosine 1-phosphate effect on endothelial cell PAF synthesis: role in cellular migration. J Cell Biochem 2003;90:719-31.
45. Lesur O, Bernard A, Arsalane K, et al. Clara cell protein (CC-16) induces a phospholipase A2-mediated inhibition of fibroblast migration in vitro. Am J Respir Crit Care Med 1995;152:290-7.
46. Kalyankrishna S, Malik KU. Norepinephrine-induced stimulation of p38 mitogen-activated protein kinase is mediated by arachidonic acid metabolites generated by activation of cytosolic phospholipase A(2) in vascular smooth muscle cells. J Pharmacol Exp Ther 2003;304:761-72.
47. Dronadula N, Liu Z, Wang C, Cao H, Rao GN. STAT-3-dependent cytosolic phospholipase A2 expression is required for thrombin-induced vascular smooth muscle cell motility. J Biol Chem 2005;280:3112-20.